Evidence map›Paper›PMID 40770411›Full record

ArticleNPJ precision oncology2025

CREB5 promotes tumorigenicity and upregulates druggable cell surface modalities in basal-like breast cancer.

Allison Makovec, Ella Boytim, Ava Gustafson, Megan Ludwig, Liangjun Wang, Atef Ali, Khalid Ishani, Christine Luo, Hannah E Bergom, Emily John and 13 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Xanthatin Attenuates Angiotensin II-Induced Cardiac Hypertrophy by Targeting CREB5.Journal of cardiovascular translational research · 2026
    Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Allison MakovecDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Ella BoytimDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Ava GustafsonDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Megan LudwigMasonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Liangjun WangMasonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Atef AliBioinformatic Interdepartmental Program, University of California, Los Angeles, CA, USA.
Khalid IshaniDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Christine LuoDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Hannah E BergomDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Emily JohnDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Sydney TapeMedical College of Wisconsin, Green Bay, WI, USA.
Samuel KellenDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Aiden DeaconDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Fatemah Iman DewjiDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Camden RichterRush University Medical College, Chicago, IL, USA.
Lauren CookleUniversity of Minnesota- Twin Cities, Minneapolis, MN, USA.
David MolineDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Jonathan P RennhackDepartment of Cancer Biology, Loyola University Chicago, Chicago, IL, USA.
Justin M DrakeMasonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Emmanuel S AntonarakisDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
David A LargaespadaMasonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Julie H OstranderDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, USA.
Justin HwangDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, USA. jhwang@umn.edu.

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008244 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI SHIMIZU, YOJI · 1988 to 2024
$13.6M
Medical Scientist Training ProgramT32GM156735 · NIGMS · UNIVERSITY OF MINNESOTA · PI YOJI SHIMIZU · 2025 to 2026
$2.6M
SRC-3/PELP1 complexes drive stem-like phenotypes in luminal breast cancerR01CA236948 · NCI · UNIVERSITY OF MINNESOTA · PI LANGE, CAROL A, OSTRANDER, JULIE H · 2020 to 2024
$2.4M
RET Regulation and Targeting in Neuroendocrine Prostate CancerR01CA269801 · NCI · UNIVERSITY OF MINNESOTA · PI Justin Michael Drake · 2022 to 2026
$2.2M
Dissecting mechanisms of sensitivity to B7-H3 (CD276)-targeted therapeutics in prostate cancer (PC)R37CA288972 · NCI · UNIVERSITY OF MINNESOTA · PI Justin H. Hwang · 2024 to 2026
$1.1M
NCI/ NIH 5R01CA236948NCI/NIH R37 1R37CA288972-01NCI NIH HHS R01 CA236948NCI NIH HHS R01 CA269801NCI NIH HHS R37 CA288972NIGMS NIH HHS T32 GM008244NIGMS NIH HHS T32 GM156735NIH NCI R01CA269801
6 · The paper itself

Abstract

Basal-like breast cancers (BLBC) have limited targeted therapies and poor outcomes. We found that CREB5 is a transcription factor overexpressed in 15% of BLBCs and was upregulated in breast cancers that metastasize to the brain. In cell lines, CREB5 overexpression regulated cell phenotypes and transcriptional changes, including IL13RA2, a cell surface receptor that is currently druggable and represents a novel target in BLBC.

Identifiers

PMID40770411
PMCPMC12328604

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.